TLR7 and neoplasm: Activation of TAA‐specific T cells, inducing tumor‐specific immunity. The DCs were used to enhance T cell proliferation and activation of CTLs. The use of TLR‐7 agonist (imiquimod) facilitated DC migration to regional lymph nodes.